Peripheral T-cell and natural killer/T-cell lymphoma are clinically and biologically heterogeneous group of lymphoid malignancies with lack of effective therapies and poor prognosis. They account for approximately 10-15% of the non-Hodgkin Lymphoma (NHL) patients among the Western countries, while the percentage elevates to 20-30% in Asia. More than 29 PTCL subtypes are identified by the present World Health Organization (WHO) classification, including the most common subtypes, such as PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T cell leukemia/lymphoma (ATLL), and extranodal NK/T cell lymphoma of nasal type (ENKTL). Recently, molecular biology technologies have been widely applied, in particular, next-generation sequencing (NGS) and gene expression profiling (GEP) techniques, which have substantially facilitated our knowledge on the PTCL subtype pathogenesis and genetic alterations. Recently, 2 PTCL-NOS biological subgroups were discovered, including PTCL-GATA3 featured by target genes (IL18RA, CCR4, IK and CXCR7) and GATA3 up-regulation, together with PTCL-TBX21 showing up-regulation of EOMES and TBX21 (T-bet) as well as the corresponding downstream targets (IL2RB, CXCR3, IFN-?, CCL3). Meanwhile, the frequent mutations in TET2, IDH2 and DNMT3A have been identified, but the molecular pathogenesis specifically to this lymphoma subtype is unknown in detail. On the other hand, systemic PTCL therapy, with the exception of ENKTL, is formulated on the basis of CHOP or similar chemotherapy. But, relapse and refractory (R/R) disorder is commonly seen among patients, in particular the high-risk cases. It is a challenge to treat cancer by PTCLs, which are usually poorly responsive to the standard chemotherapy regimens of which 5-year overall survival (OS) rates ranging from 25% to 30%. As a result, it is of urgent necessity to develop the novel targeted therapeutics to treat PTCL.
In this Research Topic, we welcome authors to submit Reviews, Mini-Reviews, Original Research, Perspective, and Clinical Trial articles focusing on, but not limited to, the following subtopics:
1. The incidence, mortality, pathology findings and clinical prognosis in peripheral T-cell and natural killer/T-cell lymphoma patients.
2. The cellular and molecular pathogenesis mechanisms study investigating genetic alteration, constitutive activated signaling pathways and deregulated tumor microenvironment in peripheral T-cell and natural killer/T-cell lymphoma.
3. The novel targeted molecular therapy and immunotherapy in peripheral T-cell and natural killer/T-cell lymphoma from preclinical and clinical trial study.
4. The molecular and genomics biomarkers predicting the clinical outcome and resistance of molecular therapy and immunotherapy treatment in peripheral T-cell and natural killer/T-cell lymphoma patients.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Peripheral T-cell and natural killer/T-cell lymphoma are clinically and biologically heterogeneous group of lymphoid malignancies with lack of effective therapies and poor prognosis. They account for approximately 10-15% of the non-Hodgkin Lymphoma (NHL) patients among the Western countries, while the percentage elevates to 20-30% in Asia. More than 29 PTCL subtypes are identified by the present World Health Organization (WHO) classification, including the most common subtypes, such as PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T cell leukemia/lymphoma (ATLL), and extranodal NK/T cell lymphoma of nasal type (ENKTL). Recently, molecular biology technologies have been widely applied, in particular, next-generation sequencing (NGS) and gene expression profiling (GEP) techniques, which have substantially facilitated our knowledge on the PTCL subtype pathogenesis and genetic alterations. Recently, 2 PTCL-NOS biological subgroups were discovered, including PTCL-GATA3 featured by target genes (IL18RA, CCR4, IK and CXCR7) and GATA3 up-regulation, together with PTCL-TBX21 showing up-regulation of EOMES and TBX21 (T-bet) as well as the corresponding downstream targets (IL2RB, CXCR3, IFN-?, CCL3). Meanwhile, the frequent mutations in TET2, IDH2 and DNMT3A have been identified, but the molecular pathogenesis specifically to this lymphoma subtype is unknown in detail. On the other hand, systemic PTCL therapy, with the exception of ENKTL, is formulated on the basis of CHOP or similar chemotherapy. But, relapse and refractory (R/R) disorder is commonly seen among patients, in particular the high-risk cases. It is a challenge to treat cancer by PTCLs, which are usually poorly responsive to the standard chemotherapy regimens of which 5-year overall survival (OS) rates ranging from 25% to 30%. As a result, it is of urgent necessity to develop the novel targeted therapeutics to treat PTCL.
In this Research Topic, we welcome authors to submit Reviews, Mini-Reviews, Original Research, Perspective, and Clinical Trial articles focusing on, but not limited to, the following subtopics:
1. The incidence, mortality, pathology findings and clinical prognosis in peripheral T-cell and natural killer/T-cell lymphoma patients.
2. The cellular and molecular pathogenesis mechanisms study investigating genetic alteration, constitutive activated signaling pathways and deregulated tumor microenvironment in peripheral T-cell and natural killer/T-cell lymphoma.
3. The novel targeted molecular therapy and immunotherapy in peripheral T-cell and natural killer/T-cell lymphoma from preclinical and clinical trial study.
4. The molecular and genomics biomarkers predicting the clinical outcome and resistance of molecular therapy and immunotherapy treatment in peripheral T-cell and natural killer/T-cell lymphoma patients.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
